| CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by … M Pfreundschuh, L Trümper, A Österborg, R Pettengell, M Trneny, K Imrie, ... The lancet oncology 7 (5), 379-391, 2006 | 2556 | 2006 |
| Follicular lymphoma international prognostic index P Solal-Céligny, P Roy, P Colombat, J White, JO Armitage, R Arranz-Saez, ... Blood 104 (5), 1258-1265, 2004 | 2169 | 2004 |
| KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma M Wang, J Munoz, A Goy, FL Locke, CA Jacobson, BT Hill, ... New England journal of medicine 382 (14), 1331-1342, 2020 | 1492 | 2020 |
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis DW Denning, P Ribaud, N Milpied, D Caillot, R Herbrecht, E Thiel, A Haas, ... Clinical infectious diseases 34 (5), 563-571, 2002 | 1106 | 2002 |
| CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the … M Pfreundschuh, E Kuhnt, L Trümper, A Österborg, M Trneny, L Shepherd, ... The lancet oncology 12 (11), 1013-1022, 2011 | 865 | 2011 |
| Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation P Colombat, G Salles, N Brousse, P Eftekhari, P Soubeyran, V Delwail, ... Blood, The Journal of the American Society of Hematology 97 (1), 101-106, 2001 | 730 | 2001 |
| Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study C Charlier, É Perrodeau, A Leclercq, B Cazenave, B Pilmis, B Henry, ... The Lancet Infectious Diseases 17 (5), 510-519, 2017 | 517 | 2017 |
| Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study S Choquet, V Leblond, R Herbrecht, G Socié, AM Stoppa, ... Blood 107 (8), 3053-3057, 2006 | 501 | 2006 |
| Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support N Milpied, E Deconinck, F Gaillard, V Delwail, C Foussard, C Berthou, ... New England Journal of Medicine 350 (13), 1287-1295, 2004 | 487 | 2004 |
| Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de … D Blaise, M Kuentz, C Fortanier, JH Bourhis, N Milpied, L Sutton, JP Jouet, ... Journal of Clinical Oncology 18 (3), 537-537, 2000 | 457 | 2000 |
| Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients N Milpied, B Vasseur, N Parquet, JL Garnier, C Antoine, P Quartier, ... Annals of Oncology 11, S113-S116, 2000 | 448 | 2000 |
| Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia JL Harousseau, JY Cahn, B Pignon, F Witz, N Milpied, M Delain, B Lioure, ... Blood, The Journal of the American Society of Hematology 90 (8), 2978-2986, 1997 | 440 | 1997 |
| Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire S Le Gouill, N Milpied, A Buzyn, R Peffault De Latour, JP Vernant, ... Journal of Clinical Oncology 26 (14), 2264-2271, 2008 | 362 | 2008 |
| High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial D Rossille, M Gressier, D Damotte, D Maucort-Boulch, C Pangault, ... Leukemia 28 (12), 2367-2375, 2014 | 361 | 2014 |
| Administration of herpes simplex–thymidine kinase–expressing donor T cells with a T-cell–depleted allogeneic marrow graft P Tiberghien, C Ferrand, B Lioure, N Milpied, R Angonin, E Deconinck, ... Blood, The Journal of the American Society of Hematology 97 (1), 63-72, 2001 | 349 | 2001 |
| Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation HG Prentice, E Gluckman, R Powles, P Ljungman, NJ Milpied, ... The Lancet 343 (8900), 749-753, 1994 | 340 | 1994 |
| Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of … C Gisselbrecht, N Schmitz, N Mounier, D Singh Gill, DC Linch, M Trneny, ... Journal of Clinical Oncology 30 (36), 4462-4469, 2012 | 337 | 2012 |
| Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as … D Blaise, D Maraninchi, E Archimbaud, J Reiffers, A Devergie, JP Jouet, ... | 334 | 1992 |
| Allogeneic marrow stem-cell transplantation from human leukocyte antigen–identical siblings versus human leukocyte antigen–allelic–matched unrelated donors (10/10) in patients … I Yakoub-Agha, F Mesnil, M Kuentz, JM Boiron, N Ifrah, N Milpied, ... Journal of clinical oncology 24 (36), 5695-5702, 2006 | 323 | 2006 |
| Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer … JY Cahn, JP Klein, SJ Lee, N Milpied, D Blaise, JH Antin, V Leblond, ... Blood 106 (4), 1495-1500, 2005 | 305 | 2005 |
